Most read alopecia, hair loss articles of 2022
As we begin the new year, Healio has compiled the most read articles of 2022 for alopecia and hair loss, which include stories about new drug treatments, the lingering effects of COVID-19 and more.
Here are Healio’s top 10 alopecia and hair loss stories of 2022:
Dutasteride may be most efficacious in androgenetic alopecia treatment
The results of this meta-analysis indicated that 0.5 mg per day of oral dutasteride has the highest probability of being the most efficacious treatment for androgenetic alopecia. Read more.
COVID-19 continues to affect hair loss
Published in July, this article detailed a study that evaluated the prevalence of hair loss in patients who had recovered from COVID-19. Results showed that of 62 patients with hair loss, histological evaluations of hair samples from 48 had telogen effluvium, 12 showed evidence of androgenetic alopecia and two showed alopecia areata. Read more.
Olumiant approved for alopecia areata treatment
The FDA’s approval of Olumiant (baricitinib, Eli Lilly/Incyte) in June made it the first systemic medication approved for the treatment of alopecia areata. The drug is a once-daily oral Janus kinase (JAK) inhibitor that was previously approved for rheumatoid arthritis and atopic dermatitis. Read more.
Ritlecitinib shows promise in alopecia areata treatment
During Maui Derm for Dermatologists, researchers presented data showing ritlecitinib was efficacious for patients with alopecia areata, with clinician-assessed efficacy and patient perception of improvement highly correlated. This JAK 3 inhibitor has shown positive results in alopecia areata patients with at least 50% scalp hair loss. Read more.
VIDEO: Shapiro describes JAK inhibitors ‘game changer’ for alopecia areata
In this video perspective from Maui Derm for Dermatologists, Jerry Shapiro, MD, FAAD, reviewed treatment options for alopecia areata, androgenetic alopecia and frontal fibrosing alopecia. Read more.
Q&A: Hair Loss Awareness Month opportunity to educate on causes, misconceptions
During August, which has been designated as National Hair Loss Awareness Month, Healio spoke with Alexander Dane, DO, a board-certified dermatologist based in Florida, about common misconceptions, current treatments and the impact of stigmas. Read more.
VIDEO: Long-term hair growth shown with baricitinib in alopecia areata
In March, Healio spoke with Brett A. King, MD, PhD, associate professor of dermatology at Yale School of Medicine, about the 52-week pooled analysis of two double-blind, placebo-controlled phase three trials he presented during the meeting’s late-breakers news session. The studies evaluated the effect of baricitinib in patients with severe alopecia areata. Read more.
Genetic analysis: Frontal fibrosing alopecia limited to scalp with no systemic involvement
Published in February, a genetic analysis found that frontal fibrosing alopecia is limited to the scalp with inflammatory milieu linked to fibrosis and no systemic inflammation, suggesting possible treatment with immune-targeting therapeutics. Read more.
Mesotherapy with dutasteride safe, effective in androgenetic alopecia
A study published in July found that mesotherapy with dutasteride was effective and associated with no serious side effects in a cohort of patients with androgenetic alopecia. The results lead researchers to believe that there are 5-alpha inhibitors that are an effective treatment for this hair loss condition. Read more.
Visual guide helps illuminate SALT scores in alopecia areata
At the European Academy of Dermatology and Venereology Congress, Brett King, MD PhD, spoke about clinicians’ unfamiliarity with using SALT scores. This measuring tool is a necessity for all clinicians, he said, as it can accurately assess the severity of the disease, providing treatment guidance. Read more.